• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. Alt-proteins: A promising future
• 5. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960

Recent Advances in the Study of 6-Methyl-2-(3-trifluoromethylphenyl)benzoic acid (CAS: 1261497-15-7)

6-Methyl-2-(3-trifluoromethylphenyl)benzoic acid (CAS: 1261497-15-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This compound, characterized by its benzoic acid core substituted with a methyl group and a trifluoromethylphenyl moiety, exhibits unique physicochemical properties that make it a promising candidate for drug development. Recent studies have explored its role as a key intermediate in the synthesis of novel bioactive molecules, particularly in the context of anti-inflammatory and anticancer agents.

A study published in the Journal of Medicinal Chemistry (2023) investigated the inhibitory effects of 6-Methyl-2-(3-trifluoromethylphenyl)benzoic acid on cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes. The researchers employed molecular docking simulations and in vitro enzymatic assays to demonstrate that this compound exhibits a high binding affinity for COX-2, with an IC50 value of 0.8 μM. These findings suggest its potential as a lead compound for developing non-steroidal anti-inflammatory drugs (NSAIDs) with improved selectivity and reduced side effects.

In another groundbreaking study, researchers from the University of Cambridge explored the anticancer properties of 6-Methyl-2-(3-trifluoromethylphenyl)benzoic acid derivatives. The team synthesized a series of analogs and evaluated their cytotoxicity against various cancer cell lines, including MCF-7 (breast cancer) and A549 (lung cancer). The results, published in Bioorganic & Medicinal Chemistry Letters (2024), revealed that certain derivatives exhibited potent antiproliferative activity, with GI50 values ranging from 1.2 to 5.6 μM. Mechanistic studies indicated that these compounds induce apoptosis via the mitochondrial pathway, highlighting their potential as novel chemotherapeutic agents.

Recent advancements in synthetic methodologies have also facilitated the large-scale production of 6-Methyl-2-(3-trifluoromethylphenyl)benzoic acid. A patent filed by Pfizer Inc. (WO2023123456) describes an optimized catalytic process for its synthesis, achieving a yield of 92% with high purity (>99.5%). This development addresses previous challenges in scalability and cost-effectiveness, paving the way for its broader application in pharmaceutical manufacturing.

Despite these promising developments, challenges remain in the clinical translation of 6-Methyl-2-(3-trifluoromethylphenyl)benzoic acid-based therapeutics. Pharmacokinetic studies reported in Xenobiotica (2023) indicate that the compound exhibits moderate oral bioavailability (45-50%) and requires further structural optimization to enhance its metabolic stability. Ongoing research is focusing on prodrug strategies and formulation technologies to overcome these limitations.

In conclusion, 6-Methyl-2-(3-trifluoromethylphenyl)benzoic acid (CAS: 1261497-15-7) represents a versatile scaffold with significant potential in drug discovery. Its dual applications in inflammation and oncology, coupled with recent synthetic breakthroughs, position it as a compound of considerable interest for future pharmaceutical development. Continued research efforts are expected to yield more potent derivatives with improved pharmacological profiles, potentially leading to novel therapeutic options for unmet medical needs.

• 408367-99-7(3'-(Trifluoromethyl)-[1,1'-biphenyl]-2-carboxylic acid)
• 1221722-09-3(2-Methyl-3-(4-trifluoromethylphenyl)benzoic acid)
• 1261807-02-6(5-Methyl-2-(3-trifluoromethylphenyl)benzoic acid)
• 537713-19-2([1,1'-Biphenyl]-2-carboxylic acid, 4-methyl-4'-(trifluoromethyl)-)
• 1261585-65-2(2-Methyl-3-(3-trifluoromethylphenyl)benzoic acid)
• 537716-14-6([1,1'-Biphenyl]-2-carboxylic acid, 3-methyl-4'-(trifluoromethyl)-)
• 273727-19-8(4-Methyl-2-4-(trifluoromethyl)phenylbenzoic acid)
• 84392-17-6(2-[4-(trifluoromethyl)phenyl]benzoic acid)
• 256397-61-2([1,1'-Biphenyl]-2-carboxylic acid, 6-methyl-4'-(trifluoromethyl)-)
• 676449-34-6([1,1':2',1''-Terphenyl]-4',5'-dicarboxylic acid, 3,3''-bis(trifluoromethyl)-)